ABSTRACT
Background In small arteries, constriction of vascular smooth muscle triggers local release of nitric oxide from the adjacent endothelial cell. This feedback vasodilation is a homeostatic mechanism that opposes vasoconstriction. Here, we investigate the role of endothelial alpha globin as a regulator of directed nitric oxide signaling across the myoendothelial junction.
Methods Human omental arteries 100-200µm in diameter were microdissected from omentum samples obtained during clinically indicated abdominal operations on NIH protocol 13-C-0176 (NCT01915225). Each artery was cannulated, perfused free of blood, and preserved for analysis or subjected to pressure myography. Preserved arteries underwent RNA extraction for gene expression; protein extraction for co-immunoprecipitation and Western blot; or immunostaining for multiphoton microscopy. Bio-layer interferometry quantified the binding of alpha globin to endothelial nitric oxide synthase (eNOS). Ex vivo pressure myography characterized arterial vasoreactivity before and after disruption of eNOS-Hb binding with an alpha globin mimetic peptide.
Results HBA1, HBA2, HBB, and NOS3 transcripts were abundant in RNA from the artery wall, and the blood cell gene SLC4A1 was not. Beta globin and eNOS co-immunoprecipitated with alpha globin in protein extracted from human omental artery segments, suggesting an eNOS-hemoglobin complex. Biolayer interferometry studies estimated alpha globin to bind to the oxidase domain of eNOS with an equilibrium dissociation constant of 1.3 × 10−6 M.
Multiphoton microscopy of intact arteries revealed alpha globin, beta globin, and eNOS to co-localize within distinct punctates in a plane defined by the internal elastic lamina that separates endothelial cells from vascular smooth muscle. Förster resonance energy transfer confirmed close physical proximity of alpha globin to eNOS in situ.
Omental arteries constricted to 39.1 ± 3.2 % of baseline diameter in response to phenylephrine. After treatment with an alpha globin mimetic peptide, the same arteries constricted to 64.6 ± 1.6% of baseline (p < 0.01). Inhibition of NOS with L-NAME restored vasoconstriction in the mimetic peptide-treated arteries to 41.9 ± 2.0% (p < 0.0001).
Conclusion Alpha globin and beta globin are expressed in the endothelium of human resistance arteries, form a complex with eNOS at the myoendothelial junction, and limit the release of nitric oxide triggered by alpha-1-adrenergic stimulation.
Phenylephrine (PE) engages alpha-1-adrenergic receptors (α1) on vascular smooth muscle cells triggering an influx of calcium (Ca++) and activating myosin light chain kinase (MLCK) to constrict muscle fibers (≈) and constrict the artery. Calcium enters the endothelial cell via putative gap junctions where it activates endothelial nitric oxide synthase (NOS) via calmodulin (CM). Nitric oxide (NO) produced by NOS can diffuse into the smooth muscle cell where it activates myosin light chain phosphatase (MLCP) via soluble guanylate cyclase and cGMP (both not shown) to relax smooth muscle fibers and dilate the artery. Hemoglobin (αβαβ) bound to NOS prevents the diffusion of NO into the smooth muscle cell likely by catalyzing the reaction with oxygen (O2) to produce nitrate (NO3-), an anion that cannot diffuse across the cell membrane. When hemoglobin is displaced from NOS with a mimetic peptide (not shown), NO diffusion increases and counteracts vasoconstriction; when NOS is inhibited by L-NAME, the mimetic peptide has no effect. Thus hemoglobin limits the diffusion of NO across the myoendothelial junction in the setting of alpha-1-adrenergic stimulation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01915225
Funding Statement
This research was supported by the Intramural Research Program of the NIH. The content of this publication does not necessarily reflect the views or policies of the U.S. Department of Health and Human Services, the National Institutes of Health, or the National Institute of Allergy and Infectious Diseases; nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. No external funding was received for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Institutes of Health Institutional Review Board, Protocol approved by NIH IRB (protocol 13-C-0176)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available from the authors by request
